Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0155 | 0 | 0.5 | |
Onchocerca volvulus | 0.0155 | 0 | 0.5 | |
Onchocerca volvulus | 0.0155 | 0 | 0.5 | |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0917 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0155 | 0 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0917 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0917 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0155 | 0 | 0.5 |
Onchocerca volvulus | 0.0155 | 0 | 0.5 | |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0917 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0917 | 1 | 1 |
Trichomonas vaginalis | spcc417.12 protein, putative | 0.0155 | 0 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0917 | 1 | 1 |
Trichomonas vaginalis | carboxylesterase domain containing protein, putative | 0.0155 | 0 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0917 | 1 | 1 |
Onchocerca volvulus | 0.0155 | 0 | 0.5 | |
Loa Loa (eye worm) | carboxylesterase | 0.0917 | 1 | 1 |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.0155 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0917 | 1 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.0917 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0917 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0917 | 1 | 1 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0155 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Average change in body weight (functional) | = -4.4 % | Average change in body weight from onset to termination of drug therapy in mice bearing the P388 Leukemia at 80 mg / kg | ChEMBL. | 7392030 |
Average change in body weight (functional) | = -4.4 % | Average change in body weight from onset to termination of drug therapy in mice bearing the P388 Leukemia at 80 mg / kg | ChEMBL. | 7392030 |
Average change in body weight (functional) | = 0 % | Average change in body weight from onset to termination of drug therapy in mice bearing the L1210 Leukemia at 120 mg / kg | ChEMBL. | 7392030 |
Average change in body weight (functional) | = 0 % | Average change in body weight from onset to termination of drug therapy in mice bearing the L1210 Leukemia at 120 mg / kg | ChEMBL. | 7392030 |
Average survival (functional) | = 14.8 day | The average survival time(days) of mice bearing the P388 Leukemia at 80 mg / kg | ChEMBL. | 7392030 |
Average survival (functional) | = 14.8 day | The average survival time(days) of mice bearing the P388 Leukemia at 80 mg / kg | ChEMBL. | 7392030 |
Average survival (functional) | = 15.2 day | The average survival time (days) of mice bearing the L1210 Leukemia at 120 mg / kg | ChEMBL. | 7392030 |
Average survival (functional) | = 15.2 day | The average survival time (days) of mice bearing the L1210 Leukemia at 120 mg / kg | ChEMBL. | 7392030 |
Survivors (functional) | = 0 | At the 50 day survivors of mice bearing the L1210 Leukemia at 120 mg / kg | ChEMBL. | 7392030 |
Survivors (functional) | = 0 | At the 50 day survivors of mice bearing the P388 Leukemia at 80 mg / kg | ChEMBL. | 7392030 |
T/C (functional) | = 157 % | Average survival time (treated / control) x100 was calculated in mice bearing the P388 Leukemia at 80 mg / kg | ChEMBL. | 7392030 |
T/C (functional) | = 157 % | Average survival time (treated / control) x100 was calculated in mice bearing the P388 Leukemia at 80 mg / kg | ChEMBL. | 7392030 |
T/C (functional) | = 169 % | Average survival time (treated / control) x100 was calculated in mice bearing the L1210 Leukemia at 120 mg / kg | ChEMBL. | 7392030 |
T/C (functional) | = 169 % | Average survival time (treated / control) x100 was calculated in mice bearing the L1210 Leukemia at 120 mg / kg | ChEMBL. | 7392030 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.